et190l1 artemis™ t cells
CD19+ Leukemia, B-Cell
First Affiliated Hospital Xi'an Jiaotong UniversityCell therapyEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
141 Active assets in the CD19+ Leukemia, B-Cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE University of Washington | Phase 3 | BBB |
VINCRISTINE SULFATE City of Hope Medical Center | Phase 3 | BB |
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) City of Hope Medical Center | Phase 3 | BB |
MERCAPTOPURINE ANHYDROUS SWOG Cancer Research Network | Phase 3 | BB |
PEGASPARGASE National Cancer Institute (NCI) | Phase 3 | BB |
View all 50 →
Same molecule, other indications
et190l1 artemis™ t cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →